The results show that apomorphine injection can effectively alleviate the fluctuation of persistent motor symptoms in patients with Parkinson's disease

Britannia pharmaceuticals Ltd announced that Toledo phase III study showed that apomorphine injection can effectively alleviate the fluctuation of persistent motor symptoms in Parkinson's patients with uncontrollable symptoms Compared with placebo, 12 weeks after hypodermic injection of apo go ® / movapo ® (apomorphine), the "closing period" was significantly shortened: apo go ® / movapo ® was shortened by 2.47 hours per day, 0.58 hours for placebo, a difference of nearly 2 hours (P = 0.0025), and the significant "closing period" for Parkinson's patients was doubled These results were observed within the first week after treatment with apo go ® / movapo ® Compared with placebo, the "open period" without dyskinesia observed after treatment with apo-go ® / movapo ® injection is called "good open period", which is significantly higher than the baseline value: apo-go ® / movapo ® increases by 2.77 hours per day, placebo by 0.80 hours (P = 0.0008), and patients can also significantly reduce the simultaneous oral administration of Parkinson's drugs (http://www.chemdrug.com/) The dosage and times of Administration (P = 0.0014) Apo go ® / movapo [® /] injection is a routine therapy for Parkinson's disease TOLEDO is the first multicenter, randomized, double-blind trial (http://www.chemdrug.com/sell/24/) to investigate the efficacy and safety of this treatment for Parkinson's disease, which was conducted in 107 patients in 23 hospitals in 7 countries Although these patients took a variety of drugs, but the symptoms are still not under control From the evaluation of patients' treatment, it can be found that the clinical results are improved: 71% of the patients who received apo go / movapo ® injection showed "improvement", while 18% of the patients who received placebo (P < 0.0001) Britannia pharmaceuticals limited, founded in 1982, is a pharmaceutical company (http://www.chemdrug.com/) headquartered in reading, UK (http://www.chemdrug.com/company/), focusing on the neurology market